A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer
Study Identifier:
DSP-5336-103
CT.gov Identifier:
N/A
EudraCT Identifier:
EU Trial (CTIS) Number:
Study Contact Information:
Will Be Recruiting
Considering participating in a START clinical trial?
Study Summary
To study enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer
Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Other
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase I
Sex
N/A
Age
N/A
Study Drug
Drug: Patients will receive enzomenib
Study Status
Indicates the current recruitment status or the expanded access status
Will Be Recruiting
Requirements information
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.
Study Locations
Location
Investigator
Status
Condition(s) Treated at Site
Location
START Madrid, Spain (FJD)
Madrid, Spain, 28040
Investigator
Status
Will Be Recruiting
Condition(s) Treated at Site
Other
Location
START Madrid, Spain (CIOCC)
Madrid, Spain, 28050
Investigator
Damian Cubillas
Status
Will Be Recruiting
Condition(s) Treated at Site
Other